Filing Details

Accession Number:
0000899243-17-024683
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-10-25 16:05:31
Reporting Period:
2017-10-23
Accepted Time:
2017-10-25 16:05:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1631650 Aimmune Therapeutics Inc. AIMT () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1222037 Md C Daniel Adelman Aimmune Therapeutics, Inc.
8000 Marina Boulevard, Suite 300
Brisbane CA 94005-1884
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.0001 Par Value Acquisiton 2017-10-23 10,000 $11.45 10,000 No 4 M Direct
Common Stock, $0.0001 Par Value Disposition 2017-10-23 5,530 $33.25 4,470 No 4 S Direct
Common Stock, $0.0001 Par Value Disposition 2017-10-23 1,470 $34.27 3,000 No 4 S Direct
Common Stock, $0.0001 Par Value Disposition 2017-10-23 3,000 $35.46 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2017-10-23 10,000 $0.00 10,000 $11.45
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
230,000 2026-06-24 No 4 M Direct
Footnotes
  1. This sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person.
  2. The transaction was executed in multiple trades in prices ranging from $32.83 to $33.81, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  3. The transaction was executed in multiple trades in prices ranging from $33.84 to $34.75, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  4. The transaction was executed in multiple trades in prices ranging from $34.87 to $35.55, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  5. The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on June 16, 2017 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.